Encephalitic Development in Alphaviral Infection by Slobodan Paessler & Katherine Taylor
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Encephalitic Development 
in Alphaviral Infection 
Slobodan Paessler and Katherine Taylor 
University of Texas Medical Branch 
United States of America 
1. Introduction 
Viruses are currently the most common cause of encephalitis. With more than 20 viruses 
known to cause human encephalitis, arboviruses, arthropod-borne viruses, represent a 
significant number of emerging infectious diseases both in the United States and world-
wide. The Alphavirus genus in the family Togaviridae contains three viruses capable of 
causing human encephalitis: Venezuelan equine encephalitis virus (VEEV), eastern equine 
encephalitis virus (EEEV), and western equine encephalitis virus (WEEV). WEEV and EEEV 
are endemic to the United States and South America while VEEV circulates in Central and 
South America; however, spread of epidemic outbreaks has resulted in disease in North 
America. No specific therapy or vaccine is currently available against these viruses. In this 
review, we summarize the development and progression of alphavirus encephalitis in both 
human populations and murine models of alphavirus infection. We concentrate on the host 
response that characterizes the development of central nervous system (CNS) disease 
following alphaviral infection. In addition, we focus on immune factors that influence 
successful resolution of infection.  
Alphaviruses represent a significant public health threat as both emerging infectious 
diseases and possible agents of bioterrorism. Natural, endemic infections of alphavirus 
disease are currently absent in certain areas of the globe where the mosquito vector capable 
of transmitting alphaviruses exists making potential virus introduction into such unaffected 
areas a significant public health concern (Calisher, 1994; Hawley & Eitzen, 2001; Weaver & 
Barrett, 2004; Zacks & Paessler, 2010). Additionally, many of the encephalitic alphaviruses 
are highly stable as an aerosol, cause significant mortality or incapacitating disease, and 
grow rapidly in easily utilized, readily available cell culture systems. This combination of 
factors makes this group of viruses of significant interest for biodefense in the United States 
(Hawley & Eitzen, 2001; Weaver, 2005).  
One of three of the original serological groups of arboviruses, the group A complex became 
the Alphavirus genus within the Togaviridae family representing enveloped, plus-strand RNA 
viruses (Porterfield, 1975; Porterfield, 1986). Pathogenic alphaviruses can be roughly 
grouped further by a combination of phylogenetics, geographical circulation, and disease 
manifestation into two groups. Viruses circulating in the Old World (Europe, Asia, and 
Africa) typically cause arthralgia, malaise or a rash. (Griffin, 2007; Zacks & Paessler, 2010). 
New World alphaviruses’ infections result in a flu-like syndrome that may progress to 
neurological involvement. New World encephalitic alphaviruses include EEE, WEE, and 
www.intechopen.com
 
Non-Flavivirus Encephalitis 
 
204 
VEE complex viruses. Of these the primary causes of neurological involvement and lethal 
encephalitis are WEE, EEE, and VEE viruses. More rarely, Highlands J virus, a member of 
the WEE antigenic complex, and some Old World alphaviruses may be neuroinvasive 
(Zacks & Paessler, 2010).  
Neurovirulence of the viruses associates with efficient and rapid spread of virus throughout 
the neurons of the central nervous system (CNS) resulting in pathogenesis and death of 
neuronal cells; however, the host response also represents significant determinant of 
pathogenesis and mortality (Griffin, 2007; Ryman & Klimstra, 2008). This chapter will briefly 
describe basic viral dissemination and spread in natural cycles, both enzootic and epizootic, 
followed by a more in-depth overview of the primary encephalitic alphavirus, EEE, WEE, 
and VEE encompassing the description of disease in animal and man with an emphasis on 
the host response.  
2. Overview of encephalitic alphaviruses 
2.1 History and Medical Importance 
Records of fatal encephalitis in horses in the northeastern United States date to the 19th 
century and reports of peste loca in South America exist back further though etiology of these 
infections is uncertain (Groot, 1971; Hanson, 1957). Throughout the early 20th century, 
sporadic outbreaks of encephalitis in horses continued to occur along the Atlantic seaboard 
of the United States as well as in regions of South America (Groot, 1971; Sabattini, et al., 
1985). In 1930, WEEV became the first of the encephalitic alphaviruses isolated from the 
brain of an infected equine, and isolation of EEEV closely followed(Meyer, et al., 1931; 
Tenbroeck, et al., 1935; Tenbroeck & Merrill, 1933). In 1936, an outbreak of equine disease in 
Venezuela similar to that found in conjunction with EEE and WEE presented isolates not 
neutralized by either EEE or WEE antisera. VEEV was subsequently discovered as a 
causative pathogen of equine disease (Kubes & Rios, 1939a; 1939b). Isolation of virus from 
human cases of encephalitis associated with epizootic outbreaks followed for all three of the 
viruses (Casals, et al., 1943; Feemster, 1938; Howitt, 1938). 
The largely summer occurrence of epidemic disease and disappearance in fall and winter 
months suggested a mosquito vector and Kelser subsequently demonstrated transmission of 
WEE virus by mosquitoes (Kelser, 1937). Since that time the EEE, WEE, and VEE viruses 
have been isolated from mosquitoes, horses, humans, and other vertebrate species, namely 
birds and rodents (Griffin, 2007). A more detailed history of each virus will be presenting in 
the sections below. 
2.2 Molecular biology of the Alphavirus genus 
The virions of the encephalitic alphaviruses contain a single-stranded, positive sense RNA 
genome composed of 5’ non structural proteins (NsP) and 3’ structural proteins totalling 12 
kilobases. The first two-thirds of the genome encode non-structural proteins NsP1, NsP2, 
NsP3 and NsP4 (Frolov, 2004; Griffin, 2007). The structural proteins are encoded in the 3’ 
third of the genome and translated from a 26S subgenomic promoter resulting in production 
of the five protein products, the capsid (C), and envelope proteins 1-3 (E1-E3) and 6K 
(Griffin, 2007). The structural proteins are considered the primary targets for adaptive, 
antigen specific immunity, both humoral and cell-mediated, and are also capable of 
interfering with host defense mechanisms (Aguilar, et al., 2008a; Simmons, et al., 2009). A 
more detailed description of specific viruses will be included in the sections below.  
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2.3 Transmission cycles  
Alphaviruses circulate in enzootic and epizootic cycles between hematophagous arthropods 
and vertebrate animals. The nature of the vertebrate host determines the maintenance of 
virus in epizootic or enzootic cycles. As such, vertebrate hosts can be loosely divided into 
two groups: the natural vertebrate host acting as the primary source of mosquito infection in 
which the virus replicates, but no symptomatic disease presents and vertebrates that 
develop symptomatic disease where ability to transmit the virus back to mosquito 
populations varies based on strain and infected host species. For the encephalitic 
alphaviruses, the primary host is typically murine or avian (Calisher, 1994). In epizootic or 
epidemic cycles, infected mosquitoes transmit the virus to a secondary host, usually man or 
equine. Large outbreaks of disease occur when infected secondary hosts act to amplify viral 
replication and transmission generating a high titer viremia permitting further infection of 
mosquito, and, subsequently, host populations. The ability of the secondary host to amplify 
the virus furthering epidemic spread varies based on virus and host, and is detailed 
specifically below (Weaver, 2005; Weaver & Barrett, 2004; Zacks & Paessler, 2010). Epizootic 
outbreaks in equines frequently signal the beginning of epidemic spread of virus followed 
by subsequent disease in human populations.  
2.4 Virus spread  
Due to the nature of infection and prevalence of asymptomatic infections, much of what is 
known about the virus spread has been determined utilizing murine models. As the 
mosquito feeds on the experimental host, virus is deposited in infected saliva 
extravascularly (Turell, et al., 1995). Virus initially replicates at the site of inoculation, 
typically skeletal muscle or immune cells, and dissemination to dendritic cells or 
Langerhans cells of the skin closely follows (Grimley & Friedman, 1970; Johnston, et al., 
2000; Liu, et al., 1970; Murphy & Whitfield, 1970). As these infected cell populations migrate 
to the draining lymph nodes (DLN) for the site of inoculation, the virus spreads through the 
blood to other skeletal muscles and through lymph and blood to lymphatic tissue. As the 
virus continues replication, spread occurs to secondary sites of replication which include the 
brain and spinal cord neurons (Griffin, 2007). While tropism of other cells of the CNS apart 
from neurons is uncertain, alphaviruses may be capable of replication in the meningeal cells, 
ependymal cells, and other glial cell populations (Ehrengruber, et al., 2003; Mims, et al., 
1973; Schoneboom, et al., 1999a). 
2.5 Pathogenic sequence of alphaviral infection in humans 
Upon virus infection the disease progression in humans typically follows a biphasic disease 
process characterized by a mild, flu-like illness potentially associated with replication at the 
primary site of infection, viremia, and initiation of the immune response (Calisher, 1994). 
Length of acute disease varies with virus, but patients typically improve slightly following 
initial illness then develop a second febrile episode congruent with dissemination of virus to 
target tissues and development of an adaptive immune response (Brown, 1993; CFSPH, 
2008; Zacks & Paessler, 2010). During this second phase, a subset of patients progress to 
neurological involvement associated with mortality. Typical lesions in fatal cases appear as 
severe inflammation of the gray matter with neuronal degeneration, infiltration of 
inflammatory cells, gliosis, perivascular cuffing and hemorrhages (Griffin, 2007). Despite the 
close phylogenetic relation of VEE, WEE and EEE complex viruses, the genotypes vary 
significantly in disease, mortality rates, severity of sequelae, and location and pattern of 
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lesions in the brain as detailed below for individual viruses (Luers, et al., 2005; Steele & 
Twenhafel, 2010; Weaver & Barrett, 2004).  
2.6 Host response 
Again, as with viral transmission most of what is known regarding the host response has 
been determined in small animal and non-human primate (NHP) models. The host response 
has been primarily characterized by the early production of type I interferon (IFN) and the 
later production of virus-specific neutralizing antibody (Adler & Rabinowitz, 1973; Grieder 
& Vogel, 1999; Houston, et al., 1977; Konopka, et al., 2009; Schoneboom, et al., 2000d). This 
set of viruses is sensitive to the effects of the type I IFNs, IFN-ǂ and IFN-ǃ, and, as a result, 
have developed evasive mechanisms of interference with type I IFN signaling. Thus, the 
ability to resist type I IFN is considered a factor for the level of virulence of WEE, EEE, and 
VEE virus strains, and mutations altering type I IFN resistance result in attenuation of the 
virus. Early control of viral replication is dependent on type I IFN production and the 
absence of type I IFN signaling is typically fatal in murine models (Aguilar, et al., 2008a; 
Aguilar, et al., 2005; Frolov, 2004; Grieder & Vogel, 1999; Jahrling, et al., 1976; Spotts, et al., 
1998). Conversely, prophylactic treatment with type I IFN or artificial induction of type I 
IFN prior to infection provides protection or extended time to death in murine models 
(Julander, et al., 2008a; Julander, et al., 2007; Julander, et al., 2008b). Viral load in target 
organs and viremia typically correlates with amount of IFN produced (Ryman, 2008).  
Interestingly, other models of CNS pathogenesis with no viral etiology demonstrate a role 
for type I IFN in an anti-inflammatory capacity capable of modulating the early, acute 
response and altering the adaptive immune response in the CNS (Galligan, et al., 2010; 
Plosker, 2011). The overwhelming pro-inflammatory cytokine response associated with 
initiation of the immune response to the encephalitic alphaviruses has been loosely linked to 
neuropathogenesis apart from viral load and replication in neuronal cell populations (Dikii, 
et al., 1976; Koterski, et al., 2007; Mokhtarian, et al., 1996; Phillpotts, et al., 2003; Ryman, 
2008; Schoneboom, et al., 2000b; Valerol, et al., 2008). Thus, the pleiotropic nature of type I 
IFN may induce a more forgiving environment in the CNS, reducing levels of 
proinflammatory cytokines, altering the adaptive response, and buffering the 
microenviroment of the CNS during alphaviral infection (Plosker, 2011). However, other 
effects of type I IFN in the CNS pathologies of alphavirus infection remain to be explored. 
Resolution of infection and disease has focused on the neutralizing antibody response to 
infection. Antibody is undoubtedly significant in recovery from peripheral infection and in 
blocking neuroinvasion (Bedenice, et al., 2009; Burke, et al., 1977; Calisher, et al., 1986a; 
DeMeio, et al., 1979). However, its effectiveness once neuroinvasion occurs is not well 
understood. Peripheral passive transfer of antibody has little effect following neuroinvasion; 
however, production of antibody from B-cells resident in the CNS may impact course of 
neurological disease though little is known about the presence or role of B-cells in the CNS 
microenviroment (Yun, et al., 2009). More recently, T-cells, particularly CD4+ T-cells, have 
been implicated in resolution of CNS infection with these neurotropic viruses (Brooke, et al., 
2010; Paessler, et al., 2007; Yun, et al., 2009). Additionally, the early production of TNF-
alpha, IL-1, and IL-6 indicates a T-helper 1 (Th1) bias to the adaptive immune response 
following alphavirus infection (Valerol, et al., 2008). The Th1 response is characterized by 
predominately IFN-Ǆ producing CD4+ T-cells (Brooke, et al., 2010; Yun, et al., 2009). As a 
corollary, IFN-Ǆ secretion associated with a Th1 response may be partially protective 
following entry of virus to the CNS (Paessler, et al., 2007). 
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3. Western equine encephalitis  
3.1 History and significance 
Initially isolated from the brain of an infected equine in 1930 in California, WEE virus was the 
first of the encephalitic alphaviruses to be discovered(Meyer, et al., 1931). However, the virus 
was not recognized as a cause of human illness till isolation from the brain of an infected child 
in 1938 (Howitt, 1938). According to the United States Center for Disease Control (CDC) and 
the Center for Food Security and Public Health (CFSPH), 640 confirmed or probable human 
cases of WEE occurred between 1964 and 2009 in the United States alone (CDC, 2009b; CFSPH, 
2008). Overall case fatality rates are estimated at 3-7%, but mortality rates depend on both age 
and other factors such as virus strain, dose, and route of infection (Calisher, 1994; CFSPH, 
2008; Hanson, et al., 1967; Ryzhikov, et al., 1991; Steele, et al., 1998; Steele & Twenhafel, 2010; 
Zacks & Paessler, 2010). Accidental, artificial exposure of aerosolized virus in laboratory 
settings has been documented with the few cases demonstrating a 40% fatality rate (Fothergill, 
et al., 1939; Gold & Hampil, 1942; Hanson, et al., 1967; Helwig, 1940). As with all the 
encephalitic alphaviruses, higher mortality rates and incidence of neurological complications 
are associated with pediatric patients. For WEE, an estimated 90% of children under one year 
of age show severe CNS signs; additionally, an estimated 15-30% of pediatric and adult 
patients that survive neurological involvement are left with severe, permanent sequelae (Zacks 
& Paessler, 2010). Children older than one year of age show a steep increase in numbers of 
asymptomatic infections (Bruyn & Lennette, 1953; Cohen, et al., 1953). Transplacental 
transmission has been documented with all know instances surviving acute encephalitis, but 
developing subsequent neurological sequelae (Bruyn & Lennette, 1953; CFSPH, 2008; Copps & 
Giddings, 1959; Romero & Newland, 2006; Shinefield & Townsend, 1953). Thus, while overall 
mortality rates due to WEE infection are low, sequelae are significant and costly particularly in 
pediatric patients (CFSPH, 2008). A steady decline in cases since the middle of the 20th century 
has been partially attributed to changes in the natural habitat for the common mosquito vector 
due to altered irrigation practices and mosquito control programs though the true cause of 
decline remains in question (Calisher, 1994; Forrester, et al., 2008).  
3.2 Transmission cycles and geographic range 
WEE acts over a broad geographic range throughout North and South America as an equine 
pathogen; however, despite the isolation of WEE strains throughout the Americas, human 
disease appears less frequently and with decreased severity in South America (Calisher, 
1994; Sulkin, 1946; Tsai, 1991). Neither equines or humans act as amplifying hosts. Strains of 
WEE virus have been isolated from humans, horses, wild birds, and vertebrates from 
western Canada to Argentina (Calisher, et al., 1985; Reisen, 1988). Specifically, infection of 
bobwhite quails, house finches, sparrows, and domestic chickens has been demonstrated 
(Hardy, 1987; O'Brien, et al.,; Watts & Williams, 1972; Williams, et al., 1971). The virus can 
also infect some small mammals including opossum, squirrels, bats, rabbits, and hares. Like 
horses and humans, a number of these species exhibit a tangential infection and do not act 
as amplifying hosts (CFSPH, 2008; Fastier, 1952; Hardy, 1987; Kiorpes & Yuill, 1975; Reisen, 
et al., 2004; Ubico & McLean, 1995; Yuill & Hanson, 1964) Isolations of WEE viruses have 
been reported in the Veracruz region of Mexico and South America and the genetic analyses 
of isolates from Brazil and northern Argentina revealed a level of nucleotide identity >90% 
in the E2/6K/E1 coding region when compared to isolates from the US. This data suggests a 
monophyletic nature of the WEEV lineage, with an overall slow evolution (Weaver, 2005; 
Weaver & Barrett, 2004; Zacks & Paessler, 2010)  
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WEE is maintained in an enzootic cycle between a number of passerine birds and its most 
common mosquito vector, Culex; however, the virus has also been isolated from mites 
(Hammon & Reeves, 1946; Hammon, et al., 1941; Hammon, et al., 1943; Reeves, et al., 1947; 
Zacks & Paessler, 2010). The avian host is likely responsible for the distribution of virus strains 
from North to South America, and explains the widespread geographic range of the virus 
(Reisen 2010, Calisher 1994). Transmission to humans and horses occurs via bridging mosquito 
vector species whose habitat and nature results in feeding on these specific vertebrate hosts 
(Calisher, 1994; Zacks & Paessler, 2010). Bridging vectors include Ochlerotatus melanimon in 
California, Aedes dorsalis in Utah and New Mexcio and Ae. Campestris in New Mexico (Clark, et 
al., 1986; Reisen, et al., 1998; Zacks & Paessler, 2010). In temperate climates, the transmission 
cycle may be maintained through the year, but in less mild climates WEE may either 
overwinter in unidentified hosts or be reintroduced annually through passerine bird. Isolates 
of WEE have been obtained from some amphibious species, garter snakes and leopard frogs, 
indicating that WEE may be able to overwinter in such hosts (Burton, et al., 1966; Gebhardt, et 
al., 1966; Gebhardt, et al., 1964). Transovarial transmission of the virus in mosquitoes has also 
been proposed as an overwintering mechanism. However, current literature on the subject is 
inconclusive (Reeves, et al., 1954; Thomas & Eklund, 1960; Watts & Eldridge, 1975). 
3.3 Disease manifestations in humans 
WEEV infections tend to have more in common with EEEV infections than with VEEV 
though infection is associated with less severe disease and lower mortality than EEE. As 
with both other viruses, WEE infections predominately are either asymptomatic or cause 
mild disease. Disease appears after a short incubation period of two to seven days and 
associates with general flu like symptoms and often times an altered mental status (CFSPH, 
2008; Hoke, 2005; Zacks & Paessler, 2010). Typical recovery begins after approximately ten 
days of symptomatic illness (Calisher, 1994). When lethal disease occurs, mortality happens 
within seven days of symptomatic disease . A minority of infected individual will develop 
encephalitis and associated neurological symptoms: neck stiffness, confusion, tonic-clonic 
seizures, somnolence, coma and death (CFSPH, 2008; Steele & Twenhafel, 2010; Zacks & 
Paessler, 2010). Abnormal reflex responses in adults depend largely on stage of illness and 
typically consist of weakness and hyporeflexia. Disease progression is slower in adults than 
in infants which develop sudden onset of illness with fever and seizures. Both adolescents 
and older children have a prodromal phase typified by severe headaches and fever of two to 
three days followed by CNS manifestations. Unsurprisingly given the higher mortality rates, 
children display far more severe neurological symptoms with muscular rigidity, involuntary 
movements, and paralysis (Calisher, 1994; Steele & Twenhafel, 2010).  
Cerebral spinal fluid (CSF) pressure may be mildly elevated with normal glucose, protein 
and elevated leukocyte counts (<500/mm3) (Calisher, 1994; Rozdilsky, et al., 1968). While 
typical CSF white blood cell counts are in this range, they have been reported to be as high 
as 2000/mm3, (Romero & Newland, 2003; 2006). Early infection is characterized by 
polymorphonuclear cells with mononuclear cells dominating later in infection (Calisher, 
1994). A computed tomography scan (CT) of one case of neonatal WEE revealed multiple, 
symmetrical, calcifications in both hemispheres in both the insular cortex and the thalamus 
as well as dilatation of the temporal ventricles and compression of the peritroncal and 
sylvian cisterns. Electroencephalogram (EEG) showed diffuse cerebral suffering mimicking 
pathologies similar to HSV-1 encephalitis (Delfraro, et al., 2011; Romero & Newland, 2003; 
Somekh, et al., 1991).  
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Gross pathologies are limited to the CNS in lethal infections and do not appear in the 
periphery (Calisher, 1994; Steele & Twenhafel, 2010). The brain is typically edematous, but 
pathologies are primarily characterized by focal hemorrhages. These hemorrhages are 
observed in the white and gray matter throughout the brain though the basal nuclei, 
thalamus, and brain stem are the most often severely affected. Lesions also appear in the 
spinal cord (Steele & Twenhafel, 2010; Zacks & Paessler, 2010).  
Histopathologically, the brains of infected individuals demonstrate wide spread 
perivascular cuffs of lymphocytes and neutrophils. Additionally, smaller areas of focal 
necrosis with and without cellular infiltrate are found throughout the brain in the striatum, 
globus pallidus, susbtantia nigra, cerebral cortex, thalamus, and pons. A subset of lethally 
infected patients displayed predominant concentrations of brain lesions in the subcortical 
white matter (Anderson, 1984; Rozdilsky, et al., 1968).  
3.4 Disease manifestations in experimental models 
WEE has not been extensively studied in animal models. While limited and often not 
precisely representative of human infection, the span of studies in small animal models and 
non-human primates (NHP) resulted in a general idea of the pathologies and host response 
to WEE. Animal models used include mice, hamsters, cynomolgus macaques, gerbils, 
guinea pigs and rabbits (Hayles, 1972; Hayles, et al., 1970; Hayles, et al., 1972; Holbrook & 
Gowen, 2008; Hurst, 1934; Reed, et al., 2005). 
3.4.1 Mouse model 
Like in humans, age and strain of mouse infected, route of inoculations, and virulence of 
virus strain all influence the susceptibility of the host (Aguilar, 1970; Bianchi, et al., 1993; 
Logue, et al., 2009; Monath, et al., 1978; Nagata, et al., 2006). Peripheral routes of infection 
result in approximately 50% mortality with intracerebral (IC) or intranasal (IN) challenge 
resulting in more uniform, dose-dependent mortality depending on strain of virus and 
background of murine model (Hardy, et al., 1997; Julander, et al., 2007; Liu, et al., 1970).  
In suckling mice, subcutaneous (SC) inoculation results in rapid, acute disease with uniform 
mortality by 48 hours post-infection (PI). Interestingly, in infant animals, mice developed 
pathologies largely in mesodermally derived tissues, and not in the CNS or other peripheral 
organs such as the lung, liver, or heart. Histologically, these mice displayed necrotic 
degeneration of the bone marrow. Despite showing no clinical signs of illness, young adult 
mice (three to four weeks) develop widespread viral encephomeningitis associated with 
focal necrosis and perivascular cuffs similar to human disease. Additional pathological 
changes were noted in the lung, liver, kidney and brown fat though no clinical evidence of 
disease was present throughout disease course indicating the resilience of the host in the 
presence of significant CNS pathologies. (Aguilar, 1970). This age group of mice also 
develop myocardial infection and necrosis as well as peripheral lesions in the heart 
(Monath, et al., 1978). Thus, tissue tropism and susceptibility to WEE vary with age of the 
animal. 
Comparison of WEEV isolates McMillan (McM) vs. Imperial 181(IMP) in outbred CD1 mice, 
demonstrated changes time to death and mortality rates varying by route of infection and 
strain of virus used though both strains are neuroinvasive. More virulent McM causes 100% 
mortality within five days following SC injection. In contrast, IMP causes no death in 
infected animals. A similar trend was noted for aerosol, IN and intravenous routes (IV). 
Thus, while both strains are neuroinvasive, only McM is also neurovirulent. McM when 
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administered IN also causes extensive damage to the neurons of the CNS. The alterations in 
pathogenicity between the two strains are possible attributed to either slower replication of 
the attenuated strain or changes in the response to the innate immune system (Logue, et al., 
2009). Accumulated data from EEE and VEE indicate that alterations in response of the host 
and susceptibility of the virus to the immune response are a strong determinant of outcome. 
3.4.2 Hamster and guinea pig models  
Virulent strains of WEE administered by multiple routes demonstrated lethal disease in 
hamster models. Hamsters have been postulated as a working model for WEE disease due 
to high mortality observed and lesions of encephalitis found following infection. 
Characteristic pathologies associate with lethality include tachypnea, conjunctivitis, 
incoordination, and seizures (Zlotnik, et al., 1972). Both IC and peripheral infection leads to 
high viral load in the brain and severe neurological disease characterized by neuronal 
necrosis and infiltration of the meninges and Virchow-Robins space by lymphocytes 
(Holbrook & Gowen, 2008; Julander, et al., 2007; Zlotnik, et al., 1972). These pathologies are 
diffuse throughout the brain with olfactory regions begin particularly damaged. Despite the 
wide-spread nature of CNS pathologies, groups of neurons from the cerebral cortex and in 
areas of the mid-brain are typically infected with WEE indicative of bystander activation 
and killing of nearby cells resulting in disseminated pathologies (Julander, et al., 2007). 
Astrocytes do not appear to be susceptible to infection in vivo (Julander, et al., 2007). Guinea 
pigs demonstrate a severe disease similar to hamster models with death occurring in less 
than ten days following infection (Bianchi, et al., 1997; Nalca, et al., 2003a).  
3.4.3 Nonhuman primate model 
WEE causes lethal encephalitis in non-human primates: cynomolgus macaques and rhesus 
monkeys (Macaca mulatta) (Hurst, 1936; London, et al., 1982; Reed, et al., 2005; Wyckoff & 
Tesar, 1939). IC and IN challenge with WEE results in severe lethal encephalitis in NHP with 
IC infection resulting in uniform fatalities and IN or aerosol challenge resulting in severe 
CNS infection with some associated mortality. Peripheral routes of challenge including 
endermally, intramuscularly (IM) or IV do not result in consistent CNS infection (Hurst, 
1936; Wyckoff & Tesar, 1939).  
Following aerosol inoculation, cynomolgus macaques develop a fever between four and five 
days and show symptomatic disease including reduced appetite, decreased behavior, and 
tremors. Leukocytosis, serum glucose levels, and fever associated with severity of disease 
though none accurately predict survival vs. mortality. Viral antigen was only detected in the 
CNS and not the periphery of lethally infected animals possibly attributed to the later time 
point of collection following clearance of virus from the periphery by neutralizing, serum 
antibody. Antigen appeared in the CNS in the neurons, microglia and Purkinje cells. 
However, virus was focused in areas of inflammation and demyelination. Interestingly, 
virus was not detectable in the blood or by throat swab during the course of infection 
suggestive of entry of WEE to the CNS through the olfactory nerves (Reed, et al., 2005). 
Thus, aerosol inoculation of WEEV in NHPs appears to be limited to the brain.  
Gross findings were also limited to the CNS and consisted of meningeal congestion with 
histological lesions characterized by meningoencephalitis. Microscopic changes included 
alteration of the Virchow-Robins spaces of the brain and some spinal cord sections by 
infiltrating lymphocytes and monocytes, as well as foci of necrosis containing lymphocytes, 
microglia, and some neutrophils, discrete glial nodules and areas of neuronal demyelination 
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(Reed, et al., 2005; Wyckoff, 1939). These studies combined with clinical findings in man 
indicate that aerosolized WEEV is infectious through the olfactory neurons, and likely does 
not affect the peripheral organs.  
3.5 Host response in experimental models 
Due to the limitations of WEE studies and lack of clinical cases, little is known about the 
pathogenic and protective mechanisms mediating WEE in natural infections, and 
experimental models are responsible for most of the current knowledge of WEE 
pathogenesis and immunology. This section details the innate immune response to WEE 
and related therapeutics followed by knowledge of the adaptive immune response and 
effective vaccination measures to induce a useful memory response. 
3.5.1 Innate immune response to WEE 
The innate antiviral immune response is a crucial mechanism to control viral replication 
prior to induction of an adaptive immune response. In addition, the early immune response 
also molds the quality and phenotype of later immune responses and may be critical in 
control of pro-inflammatory pathogenic mechanisms following infection. Unfortunately, 
little is known about innate immune mechanisms important in alphavirus infection apart 
from a role for type I IFN Like other alphaviruses, WEE is sensitive to the effects of IFN-ǂ 
and IFN-ǃ. Recombination events that lead to the formation of the WEE from SIN- and EEE-
like ancestors was essential for the virus to gain the ability to shut off transcription of anti-
viral IFN factors, and likely lead to the emergence of WEE as a pathogenic virus 
(Garmashova, et al., 2007a; Garmashova, et al., 2007b; Weaver, et al., 1997). In vitro 
examination of human neuronal cells response to WEE indicates that virus cytopathology is 
reduced depending on maturation state of neurons in a manner independent of autocrine 
type I IFN activity and may explain the age related susceptibility to WEE infection. 
Additionally, mature neuronal cells were more sensitive with five to ten-fold less type I IFN 
needed to reduce viral cytopathology and replication. Type I IFN treatment is unable to 
completely eliminate WEEV cytopathogenicity in neuronal cells lines indicating factors 
apart for type I IFN may be important in control of viral replication (Castorena, et al., 2008). 
 Pre-treatment of hamsters IP with either a consensus type IFN-ǂ , or with Ampligen®, a 
stimulator of Toll-like receptor 3 and subsequently type I IFN expression, resulted in 
complete survival compared to 100% lethality in controls (Julander 2007). Additionally, 
surviving animals treated with IFN were less symptomatic and lost less weight than 
controls. Both compounds acted as effective anti-virals significantly reducing the viral load 
in the brain at four days PI (Julander, et al., 2007).  
A single dose of adenovirus-construct expressing transient INF-ǂ (Ad5-mIFN-ǂ) is capable 
of prophylactic and some therapeutic protection in mice against lethal, intranasal WEE 
challenge. The construct when administered 24 h, 48 h, or 7 d prior to infection provides 
100% protection and when given 6 h PI provides 60% protection associated with delayed 
progression of disease. Clinical signs of infection were decreased in animals receiving the 
Ad5-mIFN-ǂ. When animals received the vectored cytokine at 13 weeks prior to infection, 
survival rates were reduced to 38% and delayed time course of infection compared to sham 
treated controls. These animals lacked observable IFN in serum. The authors hypothesize 
that the discrepancy between serum IFN and protection could be due to continued higher 
levels of IFN in the brain providing protection following decrease of serum IFN (Wu, et al., 
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2007b). Thus, when given prior to infection, IFN-ǂ treatment provides rapid, lasting 
protection, and is indicative of the importance of a rapid, strong innate immune response. 
3.5.2 Adaptive immune response 
Much of what is known about the adaptive immune response to WEEV is derived utilizing 
models of pre-existing immunity, particularly regarding the antibody response. Currently, 
little is known about other mechanisms of cell mediated immunity. 
3.5.2.1 Antibody response 
Vaccination studies in experimental models provide the main basis of what is currently 
known about immunoprotection to CNS infection with WEE. Early studies in the 1970’s on 
the efficacy of formalin inactivated WEE vaccine in humans demonstrated immunogenicity 
following a series of two vaccinations. Recipients developed high levels of serum 
neutralizing antibody 28 days following final vaccination. High levels of neutralizing 
antibody were present through day 360 with the exception of one recipient (Bartelloni, et al., 
1971). Currently, a similar formalin inactivated vaccine is available under investigational 
new drug (IND) status for vaccination of at risk laboratory workers and personnel (Hoke, 
2005). The poor immunogenicity of the inactivated vaccine however requires three 
immunizations and annual boosts to be effective (Hoke, 2005; Smith, et al., 1997)  
Live-attenuated vaccine candidates generate rapid protection associated with high levels of 
neutralizing antibody in animal models (Atasheva, et al., 2009; Schoepp, et al., 2002). DNA 
vaccination is able to completely protect mice against WEE; however, as with the inactive 
vaccine, three immunizations are required to achieve high levels of protection (Nagata, et 
al., 2005). A single dose of adenovirus vectored WEE vaccine protects against intranasal 
challenge of WEE, but use of adenovirus vectors is associated with significant risks (Barabe, 
et al., 2007; Wu, et al., 2007a). Chimeric alphavirus vaccine candidates combining the non-
structural proteins of one alphavirus with the structural proteins of WEE provide protection 
in mice from IN challenge with WEE. Vaccination studies indicate that high level, long-
lasting neutralizing antibody is capable of protecting mice from a variety of routes of WEE 
infection (Atasheva, et al., 2009).  
Early studies focused on antibody and complement. Yoshino, et al. showed both early and 
late forming antibodies demonstrated enhanced virus neutralizing activity when in the 
presence of complement (Yoshino, et al., 1971). Jahrling et al. demonstrated that immune 
elimination from immunized hamsters involved formation of virus/antibody aggregates 
cleared by the reticuloendothelial system. Virulent strains of WEE were cleared slowly from 
the circulation of non-immune hamsters, but were rapidly cleared when inoculated into 
immunized hamsters. Mixtures of virus and specific immune sera and from inoculated 
animals formed aggregates of virus and antibody. Further studies showing more efficient 
adsorption of WEE by macrophages in the presence of complement led the group to 
hypothesize that immune clearance of the virus in the intact hamster involves a complement 
dependent interaction of virus/antibody complexes with cells with Fc and complement 
receptors (Jahrling, et al., 1983). Thus, the role of antibody dependent cytotoxicity of infected 
cells remains unclear based on these early studies. However, antibody is well-established as 
an important factor in the clearance of virus. 
Furth studies utilizing hyperimmune sera clarified the role of antibody production in the 
periphery. Hyperimmune sera from rabbits or equines was experimentally tested and 
appeared to be efficacious in certain scenarios, again indicating the importance of a robust 
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antibody response in limiting viral pathologies (De Boer, et al., 1955). Hyperimmune 
horse sera administered to rhesus monkeys at time of development of symptomatic 
disease had no effect on disease course following IN infection. However, prophylactic or 
early (within 24 h) administration provided passive protection, but not sterilizing 
immunity(Wyckoff & Tesar, 1939). Some mouse monoclonal antibodies were shown some 
of these antibodies were shown to provide protection from infection following passive 
transfer of antibody (Long, et al., 2000; Long, et al., 2001). Mice were protected from 
challenge with WEE when injected with antibodies against E1 and E2 in passive transfer 
studies (Hunt & Roehrig, 1985; Yamamoto, 1986). Administration of an E. coli expressed 
E2 protein into mice demonstrated that immunization of this structural component of E2 
could partially protect mice from lethal challenge with WEE, and was associated with a 
strong cell mediated immune response (Das, et al., 2007). The E1 protein has also been 
successfully developed as a vaccine target. Delivery of both E1 and E2 proteins by an 
adenovirus delivery vector offer complete protection against lethal challenge from WEE. 
Mice given a single dose of vectored E1 alone were also completely protected (Swayze, et 
al., 2010). The B-cell antibody mediated response and the T-cell responses are intertwined 
and quite likely both play significant roles in the mediation of infection. However, their 
specific place following infection of the CNS remains. 
3.5.2.2 Other cell-mediated immune responses 
In an early paper published in the late 1980’s on the Th immune response, stimulation of 
both primed T-helper cells and B-cells resulted in a virus specific proliferative responses 
against the immunizing virus. Proliferating T cells were primarily IL-2 secreting Thy-I 
positive, Lyt-l positive, Lyt-2 negative, and L3T4 positive. This study indicated a Th1 bias to 
the immune response as well as suggesting highly specific WEE T-cell epitopes mediated 
the generation humoral immunity and neutralizing antibody. (Mathews & Roehrig, 1989).  
Prophylactic administration of cationic liposome-DNA complexes in CD-1 outbred mice 
challenged with WEEV-McM by either SC or aerosol routes results in significant protection. 
Protection is associated with increased serum and brain levels of IFN-gamma, TNF-alpha, 
and IL-12 as well as increases in MCP-1 and IL-10 in the brain after neuroinvasion. Thus, a 
strong-non specific activation of the innate immune system with a distinct Th1 bias elicits 
protection in the absence of pre-exisiting memory response (Logue, et al., 2010). 
Administration of an E1 adenovirus vectored antibody also induced a strong WEE specific 
T-cell response associated with increased secretion of IFN-Ǆ (Swayze, et al., 2010). The 
current literature indicates that a predominate Th1 response characterizes the adaptive 
immune response; however, much work remains to determine specific phenotypes of T-cell 
populations and to further corroborate the direct and indirect contributions of both antibody 
and T-cells.  
4. Eastern equine encephalitis  
4.1 History and significance 
EEE is considers the most severe of the arboviral encephalids in North America with 
mortality from encephalitis in epidemics ranging from 30-75% (CFSPH, 2008; Zacks & 
Paessler, 2010). Even in the absence of immediate mortality, CNS infections typically result 
in death following recovery from acute disease with initial mortality rates of 74% 
progressing to 90% by 9 years after infection with only 3% recovering completely. Intitial 
survival following CNS symptoms leaves most patients with disabling sequela and 
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neurological impairment. However, in the absence of neurological symptoms, infections 
typically resolve within one to two weeks (Morris, 1988). 
In the US and Canada, a steady decline in number of cases since 1955 has occurred (Zacks & 
Paessler, 2010). From 1964 to 2009, an estimated 260 cases of EEE occurred in the United 
States with an average of four to five cases yearly though the number can vary markedly 
from year to year. Additionally, only 83 cases were reported from 1998 to 2009 (CDC, 
2009a). As with the other encephalids, risk of symptomatic EEE infection with neurological 
complications is higher in children, particularly infants (<1 year of age), and the elderly 
(Calisher, 1994; CFSPH, 2008; Zacks & Paessler, 2010). Early reports indicated symptomatic 
cases are primarily pediatric with a large portion (42%) being younger than one year of age 
(Feemster, 1938; 1957; Feemster & Haymaker, 1958). However as with WEE, decline in EEE 
indicative of changes in mosquito control practices and living conditions has altered the 
phenotype of cases and later reports indicate overall pediatric cases likely account for 20% 
of reported cases (Deresiewicz, et al., 1997; Przelomski, et al., 1988; Romero & Newland, 
2003). However, the presence of both vector and host populations throughout North 
America indicated that cases of asymptomatic infection may be underreported (Weaver, 
2005). 
Given the preceding discovery of WEE, EEE likely existed in natural cycles long before its 
first isolation in 1933 from the brain of an infected equine (Tenbroeck, 1933). Corroborating 
this, reports of outbreaks of equine disease similar to EEE exist as early as 1831 (Feemster, 
1957). The virus was first isolated from human brain tissue in 1938, and since that time has 
been attributed to epizootics and as a cause of avian disease (Brown, et al., 1993; Webster & 
Wright, 1938; Zacks & Paessler, 2010). While EEE was suspected to cause epidemic human 
disease following isolation, an outbreak involving 38 infants, children and adults formally 
linked EEE to epidemic disease (Farber, 1940; Feemster & Haymaker, 1958).  
4.2 Transmission cycles and geographic range 
The virus is found primarily on the Atlantic seaboard, but infections have been noted in the 
upper Midwest United States and southeastern Canada (Calisher, 1994). The virus has been 
isolated from birds and other mammals such as equines, sheep, cattle, and deer as well as 
mosquitoes throughout these regions (Carman, et al., 1995; Gibbs, 1976; McGee, et al., 1992; 
Schmitt, et al., 2007). Cotton rats and house sparrows have been proposed as other hosts for 
the virus (Arrigo, et al., 2010). Annual or recurrence of virus in enzoonotic habitats 
represents typical transmission with extension to other ranges based on the primary avian 
host range (Calisher, 1994). Overwintering mechanisms have been poorly studied, but 
vertical transmission from mosquitoes or, as with WEE, reptiles may explain persistence 
during the winter months (Cupp, et al., 2004; LeDuc, et al., 1975; Morris & Srihongse, 1978). 
Alternatively, the virus may be reintroduced annually from passerine birds. Horses and 
humans, as with WEE, are considered dead end hosts, though equines may act as an 
amplifying host in regions where they are high concentrations of both equines and 
mosquitoes(CFSPH, 2008; Zacks & Paessler, 2010). Cs. melanura mosquitoes are the accepted 
primary enzootic vector transmitting EEE between passerine birds, but rarely transmit the 
virus to equines or humans (Andreadis, et al., 1998). The transmission of EEE to humans 
and equine occurs via other mosquito populations such as Coquillettidia, Aedes, and Culex 
due to their more common feeding on mammals (Andreadis, et al., 1998; Armstrong & 
Andreadis, ; Moncayo, et al., 2000; Vaidyanathan, et al., 1997).  
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4.3 Disease manifestations in humans 
As with WEE, geographic location is indicative of severity of epidemic disease in humans 
with southern isolates of disease typically causing mild or subclinical symptoms in humans, 
though outbreaks of equine disease are still associated with the South American strains 
(Causey, 1968). EEE presents as either a systemic or encephalitic syndrome depending on a 
number of external factors, but age correlates with prevalence and severity of neurological 
symptoms (Calisher, 1994; Zacks & Paessler, 2010). Infections are characterized by general 
malaise, fever and chills. Presentation includes headache of increasing severity, irritability, 
restlessness drowsiness, anorexia,, vomiting, diarrhea, cyanosis, convulsion, and coma. 
Antibody is present at time of onset of symptomatic illness, but virus can rarely be isolated 
from blood or cerebral spinal fluid (CSF) at this time point (Hauser, 1948; Steele & 
Twenhafel, 2010; Zacks & Paessler, 2010). The incubation period is thought to be somewhat 
more protracted that WEE, but reports vary and range from five to ten days. Typical 
systemic illness lasts one to two weeks and recovery is typically complete with no CNS 
involvement (CFSPH, 2008; Zacks & Paessler, 2010). In the 33% of patients exhibiting 
neurological symptoms, lethality usually occurs between two to ten days after disease 
presentation (CFSPH, 2008; Steele & Twenhafel, 2010; Zacks & Paessler, 2010).  
In infants, EEE typically results in abrupt encephalitic involvement while in older children 
and adults the disease is manifested after systemic infection that is often subclinical 
(Calisher, 1994; Farber, 1940; Morse, et al., 1992; Winter, 1956). Paralysis develops during the 
acute phase of illness with tremors and muscle twitching proceeding to continuous nuchal 
rigidity. Young children present with edema and increased CSF pressure with enhanced 
cellular presence of neutrophils. During encephalitis, fever, headache, vomiting, respiratory 
symptoms, leukocytosis, hematuria, seizures and coma may occur (Calisher, 1994). Cause of 
death is typically attributed to encephalitis, but some patients evidence myocardial damage 
and impairment of pulmonary functions, unique to EEE and differentiating pathogenesis 
from that of WEE or VEE (Deresiewicz, et al., 1997; Gutierrez & Prober, 1998; Lury & 
Castillo, 2004; Zacks & Paessler, 2010). Magnetic resonance imaging and CT images of 
infected brains demonstrate early changes in basal ganglia and thalami suggestive of edema, 
ischemia, and hypoperfusion following early, symptomatic disease (Deresiewicz, et al., 1997; 
Gutierrez & Prober, 1998; Lury & Castillo, 2004).  
Gross pathological examination of organs reveals brain edema with necrosis, facial and 
generalized edema, vascular congestion and hemorrhage in the brain and visceral organs. 
Examination of brain lesions reveals neuronal destruction and vasculitis both perivascular 
and parenchymous at the forebrain, basal ganglia, cortex, midbrain, and brain stem. Neither 
cerebellum nor spinal cord are greatly involved in infection (Bastian, et al., 1975; Calisher, 
1994; Zacks & Paessler, 2010) Histopathological changes are consistent with vasculitis, 
hemorrhage, and encephalitis and represent the primary manifestations of encephalitis 
(Deresiewicz, et al., 1997). Virus appears in oligodendroglia though primary tropism is 
neuronal (Gardner, et al., 2008; Kim, et al., 1985). Virus can also be isolated from other 
tissues post mortem.  
4.4 Disease manifestations in experimental models 
EEE causes disease in a number of animals including mice, guinea pigs, hamsters, NHP and 
some bird species such as chickens (Adams, et al., 2008; Cole & McKinney, 1969; King, 1940; 
Liu, et al., 1970; Ogata & Byrne, 1961; Olitsky & Cox, 1936; Steele & Twenhafel, 2010; 
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Wyckoff & Tesar, 1939). Experimental infections of mice, guinea pigs and rhesus monkeys 
provide the primary understanding of EEE pathogenesis (Hurst, 1934; King, 1938; 1939; 
Nathanson, et al., 1969; Olitsky & Cox, 1936; Pursell, et al., 1972; Sorrentino, et al., 1968; 
Wyckoff & Tesar, 1939). 
4.4.1 Mouse model 
While mice are an accepted model for many alphaviruses infections, they fail to reproduce 
the vascular component of disease typical for human infections making, in this case, the 
hamster model more representative to study acute vasculitis and encephalitis for EEE (Zacks 
& Paessler, 2010). However, multiple studies have been conducting in mice with valuable 
information on the pathogenesis of EEE derived from these experimental infections. Mice 
are susceptible to infection with EEE virus by cutaneous, JN, and IC inoculation as well as 
aerosol administration. Mice infected with the virus reproduce a typical biphasic disease 
course exemplified by viral replication the peripheral tissues followed by viremia, CNS 
invasion, and encephalitis. While infected mice exhibit seizures, they do not exhibit 
paralysis as seen in humans (Gardner, et al., 2008; Steele & Twenhafel, 2010). Interestingly 
no differences in mortality between 15 or 21 day and 1 year old mice are observed following 
IN infection with EEE, unlike the age dependent resistance seen in WEE infections. Infection 
by a more rigorous IC route ablates these differences in mortality(Olitsky, et al., 1936). 
EEE causes lethal encephalitis in suckling and adult Swiss albino mice following IC infection 
and causes a pantropic infection with encephalitis following SC inoculations (Liu, et al., 
1970). EEE infected mice develop minimal clinical signs of febrile illness early after 
peripheral inoculation, but progress directly and rapidly to neurological disease though 
severity varies by age of animal, route of infection, and strain of virus used . Following 
footpad inoculation, neuroinvasion results in rapid, efficient replication in the CNS inducing 
widespread infection, direct cytopathogenicity of neurons, and severe encephalitis. In young 
mice, abnormal bone formation characterized by loss of osteoblasts, reduced osteoid 
production and cartilage hypertrophy is a defining feature (Steele & Twenhafel, 2010; Vogel, 
et al., 2005). By four days PI, the virus presents in neurons and glial cells throughout the 
brain with the caudate nucleus, thalamus, and pons being the most strongly infected areas. 
Major histological changes in the brains of mice are associated with rarefaction of neuropil 
in the gray matter as well as some white matter tracks and mild inflammation characterized 
by neutrophil and eosinophil like infiltrates. In the periphery, EEE targets fibroblasts, 
skeletal muscle, and cardiac myocytes, osteoblasts, ovarian stromals cells, keratinocytes, 
sebaceous gland epithelium, odontoblasts, and ameloblast in the teeth, retinal ganglion in 
the eyes and a few olfactory neuroepithelial cells (Steele & Twenhafel, 2010; Vogel, et al., 
2005). Lymphocyte apoptosis throughout the thymus and secondary lymphoid tissues is 
widespread, but is likely not associated with active viral replication due to failure to 
replicate in these cells in vitro situations unlike WEE (Gardner, et al., 2008; Steele & 
Twenhafel, 2010). 
Rather than entry through olfactory routes as has been suggested for WEE and VEE, EEE 
appears to enter the brain directly from the bloodstream based on very rapid onset of 
disease (24 h PI), widely dispersed infection in the CNS, and absence of pathology in the 
olfactory neuroepithelium (Vogel, et al., 2005). Aerosol infection of animals indicated that 
mice infected with EEE show neuronal tropism and brain lesions similar to peripherally 
infected mice. In these animals, infection is presented at 24 hours as with peripheral 
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infection, but only presented in the olfactory bulbs and evidence of infection of the olfactory 
neuroepithelium suggesting neuroinvasion via direct infection of the neuroepithelium in 
contrast to peripherally infected animals (Roy, et al., 2009; Steele & Twenhafel, 2010). Thus, 
route of infection likely plays a significant role in mechanism of CNS entry. 
4.4.2 Hamster and guinea pig models  
Like mice, EEE also causes lethal encephalitis in hamsters and guinea pigs (Liu, et al., 1970; 
Morgan, 1941; Morgan, et al., 1942; Murphy & Whitfield, 1970). Hamsters develop biphasic 
illness like humans when infected with virulent EEE strains, and have the advantage of 
reproducing the vascular component of disease not present in mouse models (Dremov, et 
al., 1978; Paessler, et al., 2004).  
Peripheral infection results in an early visceral phase, with accompanying virema, then 
neuroinvasion, and subsequent death caused by encephalitis within four to six days post 
infection. Fever, appears within 24 hours and clinical signs of neurological systems namely 
head pressing, stupor and coma follow. However, unlike in mice targeting of the osteoblasts 
has not been reports. Virus is cleared from blood and peripheral tissues but not the brain 
following development of neutralizing antibodies(Paessler, et al., 2004).  
As with the mouse model, virus appears to be blood-borne as evidence by first appearance 
of antigen in the neuronal cells of the basal ganglia and brain stem by two days post-
infection (Dremov, et al., 1978). This early infection of periventricular and perivascular 
neuronal cells in the basal ganglia and hippocampus characterize experimental infection 
and may be due to the hypothesized blood borne nature of the virus, though data is 
inconclusive (Paessler, et al., 2004). The virus penetrates the brain rapidly and neuronal 
phase of disease develops quickly with a disseminated virus infection throughout the brain . 
Though peripheral organ infection develops with early targets including the heart, liver, 
lungs, kidneys, lymphoid tissues, and skeletal muscles, viral load in the brain is typically 
much higher (Dremov, et al., 1978; Paessler, et al., 2004).  
Peripherally affected organs may display pathological changes such as congestion and 
micro-hemorrhages as described in fatal human EEE cases (Dremov, et al., 1978; Paessler, et 
al., 2004). In animals surviving five days or more, inflammatory pathology in the brain is 
characterized by infiltrates of macrophages, lymphocytes and neutrophils (Cole & 
McKinney, 1969; Dremov, et al., 1978). Given the early presence of antigen in the basal 
nuclei, hippocampus, and brainstem, these areas are more severely affected. However, the 
cerebral cortex and cerebellum also demonstrate severe pathologies. Histopathological 
features include destruction, of neurons, inflammatory cell infiltration of the neuropil, 
gliosis, and microhemorrahages as well as vasculitis (Dremov, et al., 1978; Paessler, et al., 
2004).  
Guinea pigs infected via aerosol by EEE develop clinical signs within 24 hours (Paessler, 
et al., 2004; Roy, et al., 2009). Symptomatic disease includes decreased activity, dorsal 
tremors, and progress to coma and death. Virus infection of the neuroepithelium and 
appearance of the virus in the olfactory bulbs occurs by 24 h PI, and the virus spreads to 
the remainder of the brain by four day PI. In the brain, neurons again represent the 
primary viral target of infection, and brain lesions are typified by neuronal necrosis and 
the presence of perivascular cuffs and infiltrates in the neuropil of macrophages and 
neutrophils. Vasculitis is evident in some late stage cases and characterized by 
fragmentation of the vessel walls, intramural infiltrates of inflammatory cells, and 
fibrinoid necrosis. No peripheral organs examined had detectable infectious virus, and 
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osteoblasts were only rarely infected again in contrast to mice (King, 1938; Olitsky & Cox, 
1936; Roy, et al., 2009; Sorrentino, et al., 1968).  
4.4.3 Nonhuman primate model  
IC inoculation of non human primates results in lethal illness, but by peripheral routs causes 
subclinical infection (Steele & Twenhafel, 2010; Wyckoff & Tesar, 1939). In cynomolgus 
macaques, IN or aerosol infections result in lethal neurologic disease (Holbrook & Gowen, 
2008; Reed, et al., 2007). Aerosol infection of older cynomolgus macaques resulted in clinical 
disease characterized by fever, neurological signs, and death within five to nine days after 
challenge in 66% of infected animals. Symptomatic animals also displayed elevated white 
blood cell (WBC) counts and elevated liver enzymes indicative of infection and systemic 
dysfunction. Viremia levels varied and some animals failed to develop detectable levels. 
Pathology indicated severe meningoencephalomyelitis with widespread neuronal necrosis 
and strong signs of inflammation including perivascular cuffs, cellular debris, gliosis, 
satellitosis, edema, and hemorrhage. Reproduction of the vascular component of disease 
also occurred with vasculitis affected cerebral blood vessels. Unsurprisingly, EEE antigen 
was disseminated throughout the brain (Reed, et al., 2007). An early study performed in the 
1960’s utilized virus isolated from a fatal human case to inoculate the thalamus of rhesus 
macaques. All animals developed acute encephalitis and were euthanized by four day PI. 
Histology evidenced severe encephalitis with neuronal necrosis and loss of neurons in the 
forebrain. Inflammation was mild in comparison to the effects on neuronal cells populations 
and consisted of leptomeningitis and perivascular cuffs (Nathanson, et al., 1969; Steele & 
Twenhafel, 2010). Adult marmosets inoculated IN with an attenuated strain of EEE 
responded with asymptomatic disease following administration, and meningeoencephalitis 
when inoculated with virulent strain. Again animals did not develop detectable viremia, but 
signs of perivascular hemorrhage affecting the cerebral cortex were present (Adams, et al., 
2008). Owl monkeys are also susceptible to infection (Espinosa, et al., 2009). 
4.5 Host response in experimental models 
As with the other alphaviruses, the mechanism of host defense against EEE is poorly 
understood. However, data from experimental models corroborates the importance of type I 
IFN, but indicates that type II IFN (IFN-Ǆ) is not crucial for protection. Furthermore, 
mechanisms of attenuation related to the type I IFN response are well understood for EEE 
and require exploration in the other alphaviruses. 
4.5.1 Innate immune response to EEE 
The discovery that cellular infection with EEE virus was suppressed in the presence of type I 
IFN led to a body of research on the effect of IFN on EEE infection and vice-versa (Wagner, 
1961). A subsequent study examining the temporal effects of IFN and EEE infection of chick 
embryo and L-cells at a high multiplicity of infection showed production of high levels of 
IFN occurring with peak viral production and extensive cytopathogenecity (Wagner, 1963). 
Corroborating the protective, antiviral effects of type I IFN, studies in murine models 
determined that mice deficient in type I IFN receptors developed higher viremia and had a 
more rapid time to death. Additionally, pre-treatment of mice with type I IFN inducer 
(poly(I-C)) results in dose dependent protection (Aguilar, et al., 2005). Unlike VEE, EEE does 
not induce high levels of IFN rapidly in the serum of infected CD-1 mice. The ability of EEE 
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to antagonize type I IFN induction is cell-dependent, and the failure of EEE to quickly 
induce IFN production may be due to its inability to replicate in myeloid lineages (Burke, et 
al., 2009; Ryman & Klimstra, 2008). 
Type I IFN’s mode of action was pinpointed as antiviral and the cytokine demonstrated the 
ability to interfere with synthesis of EEE viral RNA (Armstrong, et al., 1971). Mechanistic 
studies demonstrated that artificial attenuation of EEE results in a marked increase in 
sensitivity to type I IFN associated with decreased virulence of the virus (Aguilar, et al., 
2005; Brown & Officer, 1975; Brown, et al., 1975; Gardner, et al., 2009; Murphy, 1975; 
Wagner, 1963). Combined with studies in WEE, this led researchers to hypothesize that 
differences in disease presentation and incidence in humans between South American and 
North American isolates could be attributed to IFN sensitivity (Brown & Officer, 1975; 
Brown, et al., 1975). Indeed, comparison of replication of North American and South 
American strains in IFN pre-treated Vero cells showed a depressive effect on replication of 
the South American isolates. However, in vivo, no differences in IFN induction were 
observed (Aguilar, et al., 2005). Identification of an avirulent, IFN type I and II sensitive 
South American strain capable of replication more efficient than virulent strains in mice 
brains unlike IFN resistant North American strains, identified both structural and non-
structural genes as important to generation of virulence and IFN sensitivity (Aguilar, et al., 
2008a; Aguilar, et al., 2008b). More specifically, the C protein is associated with host cell 
gene shut-off likely resulting in cell toxicity (Aguilar, et al., 2007). Amino acids 55 to 75 were 
critical to the capsid’s ability and associated with viral evasion of the anti-viral type I IFN 
mechanisms (Aguilar, et al., 2008a; Aguilar, et al., 2008b). In addition to inference with host 
cell systems, EEE may partially avoid the IFN response due to its failure to replicate in 
myeloid lineages (Ryman & Klimstra, 2008). Thus, host response and viral susceptibility to 
the host response appears to be a critical determinants of outcome 
Mice with a deficiency in the type II IFN (IFN-Ǆ) receptor demonstrate equivalent levels of 
viremia and mortality rates to wild type animals indicating that IFN-Ǆ is not crucial to 
control of murine EEE infection (Aguilar, et al., 2008a; Aguilar, et al., 2008b). Induction and 
modulation of the innate immune response helps to modulate the adaptive immune 
response, and may have unexplored downstream effects following infection. 
4.5.2 Adaptive immune response to EEE 
4.5.2.1 Antibody response 
Humans develop neutralizing antibody following infection or vaccination (Eklund, et al., 
1951). Horses, chickens, and other avian hosts develop neutralizing antibody as well 
following infection or vaccination (Barber, et al., 1978; Bedenice, et al., 2009; Calisher, et al., 
1986c; Clark, et al., 1987; Cole, et al., 1972; Edelman, et al., 1979; Elvinger, et al., 1996). High 
levels of neutralizing antibody result in mice vaccinated with EEE virion proteins. Humans 
develop diagnostically useful IgM levels allowing discrimination of different arbovirus 
populations for serological determination of infection (Calisher, et al., 1986a; Calisher, et al., 
1986b). In humans, virus specific IgM antibodies can develop as early as 24 h following 
onset of disease and persist for upwards of 3 months. IgG cannot be detected till the middle 
of the 2nd week of disease (Calisher, et al., 1986b; Calisher, et al., 1986c; Knoroz, et al., 1986). 
Individuals immunized with investigational inactivated EEE (PE-6) develop high titer 
neutralizing antibodies against E1 and E2 glycoproteins of the parent strain. However, the 
neutralizing antibody titers against a related South American strain are minimal for these 
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epitopes (Strizki & Repik, 1995). Taken together data indicated that humoral viral immunity 
is highly specific for different EEE strains.  
Immunization of guinea pig and hamster models results in protection and vaccination of 
certain avian populations has been reported to reduce numbers of infected birds (Clark, et 
al., 1987; Olsen, et al., 1997). Chimeric vaccines of EEE and WEE have also been proposed as 
have trivalent vaccines utilizing immunogens from all three encephalitic alphaviruses or 
recombinant genetic systems (Atasheva, et al., 2009; Barber, et al., 1978; Pedersen, 1976; 
Schoepp, et al., 2002). In murine models with pre-existing immunity generated via 
vaccination, neutralizing antibody is typically detected ten days following infection (Brown 
& Officer, 1975; Brown, et al., 1975). Neutralizing antibody also develops in the spinal fluid 
of rabbits vaccinated with either a live or formalin-inactivated vaccine, and such animals are 
able to resist vigorous challenge routes by IC injection of active virus. Interestingly, failure 
to resist CNS infection occurred in animals with detectable levels of neutralizing antibody in 
the serum, but lacking antibody in the cerebral spinal fluid (Morgan, 1941; Morgan, et al., 
1942). Such data indicates the importance of the immune responses in the microenvironment 
of the CNS and indicate that once virus reaches the CNS peripheral measures of protection 
may be insufficient to determine prevention of disease. 
4.5.2.2 Other cell-mediated immune responses 
Early studies in T-cell mediated immunity indicate that T-cells proliferate in a virus-specific 
manner and are predominately of a Th1 phenotype. (Mathews, et al., 1994). As mentioned 
previously EEE virus replicates poorly in lymphoid tissues, but preferentially infects 
osteoblasts in murine models. Compared to VEE, the ability of EEE to infected dendritic 
cells (DC) or macrophage populations is severely limited. However, both viruses replicate 
efficiently in other cell populations of mesenchymal lineage. Translation of EEE is inhibited 
in lymphoid tissues of myeloid lineage, but not other cells. This inhibition was shown to be 
independent of IFN responses both in vitro and in vivo. (Gardner, et al., 2008; Gardner, et al., 
2009).  
EEEV does not replicate well in lymphoid tissues in vivo on in vitro. Specifically, EEE fails to 
replicate in either macrophages or dendritic cells (Gardner, et al., 2008). Additionally, 
replication is restricted in human leukocytes in vitro (Levitt, et al., 1979). This corroborates 
with evidence from mouse models demonstrating the primary site of EEE replication occurs 
in fibroblasts, skeletal muscle and osteoblasts. Failure to replicate in lymphoid organs may 
explain the later appearance of EEE symptoms than the WEE or VEE (Gardner, et al., 2008; 
Vogel, et al., 2005). Thus, the failure of EEE to initiate significant signs of early febrile 
disease may be due to this primary tropism for the oesteoblast lineage of cells rather than 
lymphotropic nature of the VEE or WEE virus. In fact, while antigen is noted in the draining 
lymph node (DLN), serum viremia is low (Vogel, et al., 2005). 
5. Venezuelan equine encephalitis 
5.1 History and significance 
Despite lower mortality rates of VEEV compared to EEEV, of the New World alphaviruses, 
VEEV is the most important human and equine pathogen due to large epizootic and epidemic 
outbreaks associated with the virus (Weaver, et al., 2004). Isolated in 1938 from the brain of an 
infected equine, VEEV was not recognized as a significant cause of illness in man till the 1950’s 
though the virus was isolated from a lethal case of encephalitis in the early 1930s (Beck & 
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Wyckoff, 1938; Kubes & Rios, 1939b; Saleh, et al., 2009; Sanmartin & Arbelaez, 1965; Sanmartin, 
et al., 1973). Since that time, the virus has been identified as the causative agent for epizootic 
outbreaks occurring sporadically at approximately 10 year intervals from time of discovery 
through the early 1970’s. One of the largest outbreaks of VEE originated in South America, 
spread through Central America, and reached southern Texas in 1971 causing thousands of 
equine and human cases of disease (Franck & Johnson, 1971; Gibbs, 1976). Circumstantial 
evidence and isolation of vaccine strain from mosquitoes in Louisiana led to speculation that 
inoculation of equines with incompletely inactivated live-attenuated vaccine, or the presence 
of mixed virus populations in vaccine preparations led to the extensive disease spread (Brown, 
1993; Pedersen, et al., 1972). However, evidence remains inconclusive. Following this outbreak, 
epidemics and epizootics ceased only to reappear in the early 1990’s. The most recent major 
outbreak occurred in 1995 in Venezuela and Colombia in which 75,000 to 100,000 human cases 
were reported (Weaver, et al., 2004).The sporadic nature of these outbreaks is likely related to 
the viability of virus transmission to equine amplifying hosts. In the presence of sterilizing 
immunity in survivors of outbreaks or following vaccination, viral spread in amplifying hosts 
is greatly limited. Thus, the interepoozotic periods can be partially explained by resistance of 
the amplifying host as can the disappearance of epizootic or epidemic outbreaks following 
1972 through effective vaccination campaigns. However, changes in mosquito control 
programs and alterations in rural and urban living conditions impacting the mosquito vector 
may also be partially responsible for the long hiatus of epidemic outbreaks though true cause 
is uncertain(Calisher, 1994; Forrester, et al., 2008; Weaver, et al., 2004). 
While the majority of VEE cases from natural disease outbreaks are asymptomatic, 
approximately 10% of infected individuals develop an apparent infection. Of apparent 
infections less than 1% are lethal, but 14% develop neurological disease and, in pediatric 
populations mortality in apparent infections is higher (~4%) (Sanmartin-Barberi, et al., 1954; 
Sanmartin, et al., 1973; Steele & Twenhafel, 2010). In cases with CNS manifestations, 
mortality increases to as high as 35% in children and 10% in adults (Bowen & Calisher, 1976; 
Bowen, et al., 1976; Gibbs, 1976; Steele & Twenhafel, 2010). As with the other encephalitic 
alphaviruses, the prevalence of severe infections greatly increases at the extremes of the age 
spectrum with the majority of deaths seen in pediatric patients. Virus is highly infectious via 
aerosol and the virus has been responsible for numerous laboratory related exposures 
(CFSPH, 2008; Hanson, et al., 1967; Weaver, et al., 2004).  
5.2 Transmission on cycles and geographic range 
VEEV circulates in an enzootic cycle between a mosquito vector and vertebrate host, namely 
rodents and humans. In epidemic or epizootic cycle, the virus transmits between horses, 
humans and mosquitos (Watts, et al., 1998; Zacks & Paessler, 2010). Typically, multiple 
mosquito(Weaver, et al., 2004) vectors present during epizootic outbreaks, but, Ochlerotatus 
taeniorhynchus, Aedes and Psorphora, are believed to be the principal vectors responsible for 
transmission in this scenario with Culex (Melanconion) species believed to transmit the 
enzootic strains (Weaver, et al., 2004). Domestic goats, sheep, and pigs can be infected, but 
rarely show disease. Dogs and domestic rabbits are susceptible to infection and develop 
symptomatic disease though none of these hosts develop high titer viremia. The primary, 
enzootic host is thought to be rodents such as the cotton rat, but species likely vary based on 
geographic location (Johnson and Martin 1974; Johnson 1974; Gibbs 1976; Johnson and 
Varma 1976). Horses act as amplifying hosts generating a very high titer viremia, and are 
capable of transmitting the virus back to mosquitoe-to-human populations (Gibbs, 1976; 
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Paessler & Weaver, 2009; Zacks & Paessler, 2010). Long thought to be a dead end host with 
levels of viremia below the limit able to reinfect mosquito populations, humans may be 
capable of acting as the primary vertebrate host for some strains of VEEV. Namely, VEEV ID 
strains circulate in an urban cycle in Peru with transmission occurring in a primary cycle 
between humans and mosquitoes. Restriction to geographic range is based primarily on 
habitat of the mosquito vector and primary vertebrate host (Watts, et al., 1998). 
5.3 Disease manifestations in humans 
Humans present with a spectrum of diseases ranging from inapparent infections to lethal 
encephalitis. However, human infections are typically mild or asymptomatic, and severe 
encephalitis is less commonly seen. Fever, headache, convulsions, disorientation, ataxia, and 
mental depression appear in a subset of symptomatic cases, but primarily in patients under 
15 years of age (de la Monte, et al., 1985; Rivas, et al., 1997; Weaver, et al., 1996). In the event 
neurological symptoms occur and the patient survives, sequelae are common (Weaver, et al., 
2004). Virus has been isolated from throat swabs, serum and brains. Most of what is known 
of onset of disease has been determined based on accidental infection of laboratory workers 
where incubation period appears to be two to five days followed by sudden appearance of 
flu like symptoms though reports from natural disease outbreaks vary (CFSPH, 2008; Steele 
& Twenhafel, 2010). Acute disease typically lasts approximately four to six days. However, 
the disease can be biphasic with a secondary fever developing four to eight days after onset. 
During this second phase, neurological symptoms develop, though again a range is present 
from somnolence and mild confusion to seizures, ataxia, paralysis, and coma (Tsai, 1991). 
Following recovery from acute disease, patients develop generalized asthenia lasting one to 
two weeks. CSF protein and liver enzymes are typically elevated with cell counts in the CSF 
ranging from 12 to 900 WBC/mm3. An EEG tracing in one patient identified diffuse 
irregular slowing (Johnson, et al., 1968). 
Gross findings in neurological cases include cerebral edema, but gross pathology of 
infections is poorly described in the literature (de la Monte, et al., 1985; Johnson, et al., 1968; 
Steele & Twenhafel, 2010). Fatal human cases are histopathologically characterized by 
edema, congestion, meningitis, and encephalitis in the brain. Vasculitis and hemorrhage are 
more rarely found (Johnson & Martin, 1974; Paessler & Weaver, 2009; Weaver, et al., 2004). 
Lymphocytes, mononuclear cells, and neutrophils infiltrate the meninges with cells 
extending into the Virchow Robins space and neuropil in a subset of cases. In the peripheral 
organs in the majority of cases, interstitial pneumonia associated with cellular infiltration, 
alveolar hemorrhage, congestion and edema present in the lung with diffuse hepatocellular 
degeneration and few infiltrates presenting in the liver (Walton & Grayson, 1988). In 
lymphoid tissues, lymphocyte degeneration, lymphoid depletion and follicular necrosis are 
accompanied by infiltrates of neutrophils as well as vasculitis (Steele & Twenhafel, 2010).  
5.4 Disease manifestations in experimental models 
Mouse and NHP models make the largest contribution to the understanding of VEE 
pathogenesis. However, hamsters and guinea pigs are also susceptible to infection, and 
early studies in these models initiated understanding of the host response to infection.  
5.4.1 Mouse model 
Mice are highly susceptible to VEEV infection (Holbrook & Gowen, 2008; Paessler & 
Weaver, 2009; Walton & Grayson, 1988; Zacks & Paessler, 2010). The mouse model mimics 
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both human and equine disease with mice developing neurotropic disease characterized by 
lethal encephalitis and lymphotropism following a biphasic disease course (Gardner, et al., 
2008; Gleiser, et al., 1962; Steele, et al., 1998). Following peripheral routes of infection, mice 
display human like disease with progression from infection of the lymphoid tissue and 
ultimate destruction of CNS tissues. Clinical symptoms in mice include: lethargy, huddling, 
dehydration, weight loss, tremors, and paralysis or paresis with a minority of animals 
developing seizures (Davis, et al., 1994; Grieder, et al., 1995).  
The lymphotropic nature of VEE results in severe myeloid depletion in rodents and 
lymphocyte destruction in lymph nodes and spleen (Davis, et al., 1994; Grieder, et al., 1995; 
Steele & Twenhafel, 2010; Zacks & Paessler, 2010). Peripheral infection is not present late in 
disease, but high levels of infectious virus are found in the CNS with death in 
immunocompetent mice occurring five to seven days after infection (Ludwig, et al., 2001; 
Vogel, et al., 1996). 
Encephalitic pathologies vary based on background of mouse, route of inoculation and 
strain of virus (Ludwig, et al., 2001; Ryzhikov, et al., 1991; Steele, et al., 1998; Steele, et al., 
2006; Stephenson, et al., 1988; Vogel, et al., 1996). Thus, based on study design, encephalitic 
pathologies range from mild neutrophilic infiltration to neuronal degeneration, necrotizing 
vascultis and Purkinje cell destruction. Lesions appear that are surrounded by necrotic 
cellular debris, perivascular cuffs composed of mononuclear cells, rarefaction of the 
neuropil and infiltration of neutrophils lymphocytes and macrophages. These lesions spread 
following the virus by an approximately 24 h delay from olfactory bulb to more caudal 
regions (Jackson, et al., 1991; Jensen & Jackson, 1966; Ludwig, et al., 2001; Ryzhikov, et al., 
1991; Steele, et al., 1998; Steele, et al., 2006; Stephenson, et al., 1988; Vogel, et al., 1996). Once 
in the CNS viral tropism is primarily neuronal though CNS macrophages as well as 
astrocytes may become infected with VEEV, but do not appear to be a primary target 
(Jackson & Rossiter, 1997a; Schoneboom, et al., 2000b; Steele, et al., 1998; Steele, et al., 2006). 
As a result, neuronal damage is extensive and has been ascribed to both necrosis and 
apoptosis (Jackson & Rossiter, 1997b; Jensen & Jackson, 1966; Schoneboom, et al., 2000b; 
Schoneboom, et al., 2000d; Steele, et al., 2006). Neuropathology may also be attributed to 
bystander activation and death as damage to glial cells, lympohcytolysis and astrocytosis 
are reported in areas where virus is not detected (Davis, et al., 1994; Grieder, et al., 1995; 
MacDonald & Johnston, 2000b; Schoneboom, et al., 2000a; Schoneboom, et al., 2000c). 
Routes of infection mimicking natural, mosquito borne infection utilize SC or footpad 
inoculation results in infection of DC, the primary cell type for VEE infection, at the site of 
inoculation. These cells then carry the virus to the DLN where VEE begins replication 
approximately four hours after infection (Aronson, et al., 2000; Davis, et al., 1994; Grieder, et 
al., 1997; Grieder, et al., 1995; Grieder & Nguyen, 1996b; MacDonald & Johnston, 2000a). The 
virus enters the blood stream by 12 hours and reaches high levels of serum viremia followed 
by infection of other tissues, particularly lymphoid. As such, VEEV presents in the spleen, gut 
and nasal-associated lymphoid tissues, thymus, bone marrow, and non-draining lymph 
nodes(Grieder & Nguyen, 1996a; Vogel, et al., 1996). Histological lesions found in peripherally 
infected animals are both neuronal and non-neuronal (Aronson, et al., 2000; Grieder, et al., 
1997; Grieder, et al., 1995; Grieder & Nguyen, 1996a; Steele & Twenhafel, 2010). 
Aerosol or IN infection results in a direct infection of the olfactory epithelium (Pratt, et al., 
2003; Steele, et al., 1998; Vogel, et al., 1996). Other nasal epithelia tissues (respiratory or 
squamous) do not appear to become infected (Charles, et al., 1995; Davis, et al., 1995; Griffin, 
2007; Pratt, et al., 2003; Steele, et al., 1998). VEEV is proposed to reach the brain via the 
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olfactory nerve, but dental structure involvement has also been proposed (Charles, et al., 
1995; Steele, et al., 1998; Steele & Twenhafel, 2010). Direct invasion of the brain via the 
bloodstream does not seem to be significant in VEE infection. Neuroinvasion results in 
caudal spread of the virus, and ultimately, overwhelming disseminated brain infection 
(Julander, et al., 2007; Julander, et al., 2008b). Thus, all routes of infection in mice with 
virulent forms of the virus result in neuroinvasion. However, infection of the nasal cavity, 
by either aerosol or IN infection, results in more rapid entry to the CNS depending on strain 
of virus used.  
Strain of mice also is an important determinant of outcome. C3H/HeN and BALB/C mice 
vaccinated dermally with TC-83, the live attenuated vaccine strain, survive. However, 
aerosol or IN infection with TC83 results in 90-100% mortality in C3H/HeN animals unlike 
inbred counterparts BALB/C that respond with no evidence of mortality (Julander, et al., 
2007; Julander, et al., 2008c; Steele, et al., 2007; Steele, et al., 1998; Steele, et al., 2006). Similar 
experiences have shown that route of administration can alter neuroinvasion with 
nonpathogenic viruses failing to enter the CNS by peripheral routes, but exhibiting the 
ability to enter the CNS by IC, IN, or aerosol administration. However, neuroinvasion, 
regardless of route, does not always correlate with mortality and virus strains avirulent in 
the periphery may remain so once in the CNS (Grieder, et al., 1995; MacDonald & Johnston, 
2000a; Steele, et al., 1998; Steele, et al., 2006). This creates an interesting dichotomy between 
neuroinvasiveness and neurovirulence of the virus and indicates that outcome depends on 
factors beyond neuroinvasion or viral replication to generate mortality.  
5.4.2 Hamster and guinea pig models  
In guinea pigs and hamsters, VEEV causes acute, fulminant disease associated with 
extensive necrosis of lymphoid tissues, and death typically occurs prior to development of 
CNS disease making these models limited for studies of human infections and encephalitis 
(Gorelkin & Jahrling, 1975; Jackson, et al., 1991; Jahrling & Scherer, 1973a; Jahrling & 
Scherer, 1973b; 1973c; Walker, et al., 1976)  
5.4.3 Nonhuman primate model  
Like the majority of symptomatic human infections, infection in NHP represents an acute 
biphasic, nonspecific febrile disease with infection of lymphoid organs (Danes, et al., 1973; 
Gleiser, et al., 1962; Monath, et al., 1974a; Nalca, et al., 2003b; Pratt, et al., 1998; Reed, et al., 
2007; Verlinde, 1968; Victor, et al., 1956) . In a comprehensive study with rhesus macaques 
infected IP, animals developed a transient viremia and biphasic fever, but otherwise 
displayed no clinical signs of disease with complete resolution of pathologies by five weeks 
PI. Lymphoid depletion occurred rapidly by two days post-infection with extensive 
lymphoid necrosis, later followed by lymphoid hyperplasia as the animals recovered from 
infection. Lesions in the brain characterized by perivascular cuffs associated with 
lymphocytes and gliosis were also apparent and developed around six days post-infection 
starting at the olfactory bulb and spread caudally throughout the brain (Danes, et al., 1973; 
Gleiser, et al., 1961; 1962; Monath, et al., 1974b; Pratt, et al., 1998; Reed, et al., 2007; Verlinde, 
1968; Victor, et al., 1956). A range of CNS involvement presents depending on strain of virus 
utilized and route of inoculation with IN and IC inoculation being particularly severe. In 
cynomolgus macaques similar findings were reported except in the case of IN or aerosol 
infection where CNS damage is more severe and, in the case of IC infection, lethal (Danes, et 
al., 1973; Monath, et al., 1974b; Pratt, et al., 1998; Reed, et al., 2007; Steele & Twenhafel, 2010; 
www.intechopen.com
 
Encephalitic Development in Alphaviral Infection 
 
225 
Verlinde, 1968; Victor, et al., 1956). Thus, IN inoculation results in disease ranging from 
simply clinical signs of encephalitis and subsequent recovery to fulminant lethal 
encephalitis (Gleiser, et al., 1962; Steele & Twenhafel, 2010). 
5.5 Host response in experimental models 
Of the three viruses, VEEV has the best characterized animal models, and therefore the most 
is understood regarding the specific host response to infection. However, significant 
obstacles due to the high biocontaiment level and the rapid death of the host animal 
following infection resulted in alternatives to typical infection models. Thus, the majority 
studies examining host response to VEE has been generated using models of attenuated 
virus or pre-existing immunity, so to date little is known about the primary host response to 
virulent infection. 
5.5.1 Innate immune response to VEE 
Like other alphaviruses, VEEV is highly susceptible to the effects of type I IFN (Jordan, 
1973). Attenuation in enzootic strains limits the virus’ ability to interfere with type I IFN 
signaling pathways and partially explains the absence of typical disease symptoms 
following infection with enzootic strains (Grieder & Vogel, 1999; Jahrling, 1975; Jahrling, et 
al., 1976; Simmons, et al., 2009; Spotts, et al., 1998; White, et al., 2001). Conversely, epizootic 
and epidemic strains are able to limit host production of type I IFN through interference 
with signaling pathways, particularly STAT1 (Simmons, et al., 2009; White, et al., 2001a; Yin, 
et al., 2009). However, the susceptibility of enzootic and epizootic strains appears to vary 
significantly based on the virus strain(Anishchenko, et al., 2004). As with EEE, the ability to 
interfere with host transcription has been ascribed to properties of the capsid protein 
(Garmashova, et al., 2007a; Garmashova, et al., 2007b). Attenuating mutations in the 5’ 
untranslated region of the genome are associated with susceptibility of the virus to the 
effects of type I IFN. Animals genetically modified with deficiencies in type I IFN signaling 
are highly susceptible to VEE infection and, even attenuated strains are uniformly lethal in 
these animals(White, et al., 2001). Additionally, artificial induction of type I IFN or 
prophylactic administration of type I IFN delays or prevents death in animal models 
(Julander, et al., 2008b). In the case of IN or aerosol infection, the rapid entry of virus to the 
CNS results in earlier neuroinvasion and may limit or alter the effectiveness of early innate 
immune mechanisms such as IFN or other as yet other unexplored mechanisms.  
Vaccination of immunocompromised mice genetically deficient in the IFN-Ǆ receptor is only 
partially protective unlike complete protection observed in wild-type counterparts 
indicating type 2 IFN signaling is not required for complete protection unlike type I IFN 
signaling (Paessler, et al., 2007). 
5.5.2 Adaptive immune response to VEE 
5.5.2.1 Antibody response 
Current knowledge of the humoral response of the host is largely derived using models of 
pre-existing immunity (vaccination) or using attenuated strains of the virus. Early work 
identified high-level neutralizing serum antibody as essential following peripheral infection, 
and the production of neutralizing antibody is utilized as an endpoint in vaccine studies as 
well as marking efficacy of the IND vaccine, TC83, to vaccinate at risk laboratory personnel 
(Alevizatos, et al., 1967; Berge, et al., 1961; Eddy, et al., 1972; Engler, et al., 1992; Feigin, et al., 
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1967; Jochim & Barber, 1974; Pittman, et al., 1996; Walton, et al., 1972). However, more 
recent research efforts indicate that circulating antibody may be irrelevant once virus 
reaches, invades, and begins replicating in the CNS and the role of antibody produced in the 
endogenous micro-environment of the CNS has been poorly explored (Paessler, et al., 2007; 
Yun, et al., 2009). Research from Sindbis models using neuroadapted strains of this 
particular alphavirus indicate that neutralizing antibody is capable of non-cytolytic 
clearance of virus from neurons (Burdeinick-Kerr, et al., 2009; Griffin, et al., 1997; Griffin, 
2010). Primary tropism of VEE in the periphery is for dendritic cells; however, in the CNS it 
replicates in neurons where non-cytolytic clearance may be of great importance(MacDonald 
& Johnston, 2000a; Schoneboom, et al., 1999b).  
Monoclonal antibodies against specific surface glycoproteins, particularly E1 and E2, may 
act as useful therapeutic agents and may provide passive immunity to infected animals 
(Hart, et al., 2000; Hart, et al., 2001; Hart, et al., 1997; Mathews & Roehrig, 1982; Roehrig, et 
al., 1988; Roehrig & Mathews, 1985). Alterations in the E2 protein are capable of altering the 
pathogenesis of the virus and preventing neuroinvasion (Davis, et al., 1995). Since aerosol 
and IN infection bypasses the need to develop viremia to be neuroinvasive, the IgG 
peripheral neutralizing antibodies may not afford protection against nasal routes of 
infection. Studies of the antibody response indicate that not all species are equally 
protected by the same vaccines and specific IgA production at the nasal mucosal surfaces 
may play a critical role in prevention from aerosol infection (Hart, et al., 1997). More 
recent studies indicate that administration of hyperimmune sera is only effective against 
peripheral infection, and has little effect once virus invades the CNS though transfer is 
able to prolong survival probably due to depression of peripheral infection (Hart, et al., 
1997). However, the role of plasma cells or locally produced antibody in the brain by 
memory B-cells remains to be determined for this infection (Paessler, et al., 2007; Yun, et 
al., 2009). Research efforts in the 1970’s indicated that Fc-dependent clearance of the virus 
does not rely on complement (Mathews, et al., 1985). Vaccinated mice with non-functional 
B-cells (μMT deficient) are highly susceptible to intranasal infection, and when infected 
with attenuated strains develop persistent viral infection (Brooke, et al., 2010; Paessler, et 
al., 2007; Yun, et al., 2009).  
5.5.2.2 Other cell-mediated immune responses 
Recent research indicates that T-cells are crucial in recovery from VEE. Specifically, CD4+ T-
cells contribute to resolution of infection. While adoptive transfer of primed CD3+ and 
CD4+ T-cells generated via vaccination ameliorates encephalitis in vaccinated ǂǃ T-cell 
receptor deficient animals, CD8+ T-cells fail to generate protection. Vaccination of Ǆǅ T-cell 
receptor deficient animals is partially protective, but animals develop a persistent viral 
infection to 28 days. Thus, while ǂǃ T-cell subsets appear to be required for protection, Ǆǅ T-
cells do not and viral persistence in these animals may be an indirect effect of a deficit in T-
cell help for B cells in these animals (Paessler, et al., 2007; Yun, et al., 2009). Earlier studies of 
the immune response to the attenuated, live vaccine strain TC83 identified a Th 1 mediate 
immune response with local activation of CD4+ and CD8+ T-cells (Bennett, et al., 2000; 
Jahrling & Stephenson, 1984; Phillpotts, 1999; Phillpotts, et al., 2003; Phillpotts & Wright, 
1999). Later data examining transcriptional profiles in the brain and sera corroborate an 
overwhelming proinflammatory response and support the Th1 bias in response to 
infection(Davis, et al., 1994; Grieder, et al., 1997; Grieder & Vogel, 1999; Koterski, et al., 
2007). These studies indicated that T-cells are critical to the host defense against infection, 
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survival, encephalitis, and the repair of neural damage and homeostasis in the 
brain(Paessler & Weaver, 2009; Paessler, et al., 2007; Yun, et al., 2009; Zacks & Paessler, 
2010). The role of CD8+ T-cells explored previously by Jones et al. and arrived at much the 
same conclusion that CD8+ T-cells were not cytolytic or immunoprotective in VEE 
encephalitis (Jones, et al., 2003). However, given the pleiotropic roles of CD8+ T-cells and 
their significance in other viral infections the elimination of a role in VEE infection is 
doubtful. 
Functional antibody production is not required for recovery from infection with an 
genetically modified, attenuated VEE virus while T-cells were critical to complete protection 
and survival of the animals. Persistence, as seen previously in Ǆǅ deficient mice, was present 
in mice deficient in functional B-cell response (μMT knock out) and infection was less 
controlled in animals depleted of CD3, CD4 or CD8 T-cells with CD4 cells appearing to 
contribute the most significantly in viral control (Brooke, et al., 2010). 
Additionally data indicate that IFN-y secretion from these cell populations contributes to 
survival. However, their role in primary infection has not been well defined. The ability of 
animals to sustain high levels of virus in the CNS calls into question the importance of viral 
replication in host pathogenesis. Vaccinated animals maintain equivalent levels of virus to 
uninfected counterparts with differential outcome indicated that viral load is not the best 
discriminator for mortality(Paessler, et al., 2007; Yun, et al., 2009). Additionally, such 
evidence indicates that the efficacy of antivirals once the virus invades the CNS may be 
limited and therapeutic efforts may be better focused on limiting or altering the host 
response to generate a non-pathogenic response. However, further understanding of the 
host response and pathogenic and protective mechanisms of resolution of infection are 
integral to effective therapeutics development. 
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